latest news releases from the newsroom
Carl M. Casale Named Director of Nalco Holding Company
NAPERVILLE, Ill., Oct. 14, 2008 (GLOBE NEWSWIRE) -- Nalco Company (NYSE:NLC), the global leader in water, energy, air and process technologies and services that deliver savings for customers and improve the environment, announced today that Carl M. Casale had been appointed to its Board of Directors, effective October 13, 2008. The appointment brings the Board to a total of six members.
STARLIMS Technologies Ltd.
STARLIMS Technologies Schedules Third Quarter 2008 Earnings Conference Call
HOLLYWOOD, Fla., Oct. 14, 2008 (GLOBE NEWSWIRE) -- STARLIMS Technologies Ltd. (Nasdaq:LIMS), a leading provider of laboratory information management systems (LIMS), will announce its third quarter 2008 financial results on Tuesday, November 18, 2008 before the NASDAQ market opens.
Camco Financial Corporation
Camco Financial Announces Quarterly Cash Dividend
CAMBRIDGE, Ohio, Oct. 14, 2008 (GLOBE NEWSWIRE) -- Camco Financial Corporation (Camco) (Nasdaq:CAFI) announced a quarterly cash dividend of $0.0375 cents per share. The cash dividend was declared October 13, 2008 for shareholders of record on October 23, 2008 and is payable October 31, 2008.
SIGA Technologies, Inc.
SIGA to Present At The Homeland Security Investor Conference
NEW YORK, Oct. 14, 2008 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight bio-warfare pathogens, today announced that its CEO, Dr. Eric A. Rose, will be presenting at The Homeland Security Investor Conference on Wednesday, October 22, 2008 at The Ritz-Carlton Hotel in Washington, D.C.
Lexicon Pharmaceuticals, Inc.
Lexicon to Present Clinical Data for LX2931, an Investigational New Drug for Rheumatoid Arthritis
THE WOODLANDS, Texas, Oct. 14, 2008 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that the company will be presenting initial Phase 1 clinical trial results for LX2931, an orally-delivered, small molecule drug candidate for the treatment of rheumatoid arthritis and other autoimmune conditions at the annual meeting of the American College of Rheumatology in San Francisco, California. LX2931 is one of four programs in human clinical trials as part of Lexicon's 10TO10 program. Lexicon also has two additional drug candidates in formal preclinical studies.